Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BB,
I'm in. However, I think the company will already be filing 'new evidence' in case of unsuccessful en banc. This seems to be the best course of action, stalling generic launch (or, any meaningful generic volume anyways). Wait until the last possible moment to file en banc. Then, if accepted for review, keep extending. If denied, then wait until possible moment and then introduce new evidence. Then, SC perhaps?
Low key volume, no sell offs, flat for the day. Consolidation. Totally works for me.
this!
Looks like our Amicus brief will appear on this list, as well? (for AMRN case)
words of wisdom
How many months on average does it take after appellate court take to reach SC and get the decision? (whatever it may be). Maybe even if they go to SC it will buy us years here?
I wonder, before Reduce-IT was approved, their annual sales were at n-level.
Can we show use that as proof that anything above that level is de-facto upper limit for total addressable market for Marine indication? so anything beyond that (for all generics combined) is infringing?
I must disagree with you, I believe it is a very well put brief and a sound strategy.
Can't wait for it to go back to 50 so we can all start over
Not sure, but it's the same Covington firm that represented Amarin.
Today's Glaxo ruling just added about $0.50/sh to possible Amarin BO discussion
Waaaay too early IMO
"it works", no?
Lizzy,
They replaced sep with oct using same link on their website. So there is no good link.
But there is a copy of Sept. Deck on seeking alpha, that's what I was looking at yesterday.
Sep deck came out on Sep3rd, immediately following appeal decision
it's not 700 shares...
667 is the name of the LP owned by BB... they have ~20M shares (or, used to have?)
All the same stuff was included in their September presentation
That's funny and sad.
But if $15 is ever reached I"m sure I will get Hail JT plate or alike
thanks for sharing, going to make for a nice informative roadtrip!
I'm sure they were hoping to file and then settle
cheers
You're probably the only poster on the board to see black/green on a position here )
got it
I must disagree with this statement.
is the drop behind us? Was the bottom in?
one might hope...
thanks, super useful.
About 30k shares in 15 minutes at 3.93-3.99 range
But everyone's question is different. Are they really that apathetic to any investor requests?
Well, that's odd. The questions I asked don't call for such response at all.
Might I guess, they gearing up for some major announcement (are in talks for BO for example), otherwise this response totally doesn't make sense .
______
Alex- thank you for reaching out.
I understand your frustration, but I have no updates to share at this time.
Thank you for your understanding,
Elisabeth
I hope this means BO. That's the only reason to GIA or pretend to GIA in Europe.
EU is not one country. It's 27 very different countries. This better be a part of some plan.
"Europe is a big market opportunity. And we think that the potential 10 plus million patients who might benefit from VASCEPA in Europe, support a sales and commercial infrastructure, and that, in our analysis, comparing to what was available to us from partners that we can make greater value for our shareholders by launching this ourselves and rather than giving up significant piece of the economic to another company who would launch it for us.
We also think that by retaining the rights in Europe, the great – greater optionality for us to be able to consider strategic opportunities both potentially and in multiple [directions] adding products or doing something with a larger company at some point in the future. The market in Europe is large. The approval process is progressing. We do think we're on track for approval in the early part of the coming year. We've hired a very experienced head on the commercial side of things, who has been through this before and knows a lot of people and how to operate within these countries."
(all you knows are omitted)
Can't say 2024 but I'm willing to wait 'somewhat'
Yep, I'm. Accounting for that. This quarter actually has two shorts week (7/4 and Labor day), still trending to ATH
When meeting notes are posted
CHMP
Sent you an email.
Also, might I suggest, in addition to court filing, can we do something like Newswire / ihub wire PR, hopefully we can make it dramatic enough to be picked up by some biopharma industry watchers/followers.
After all, this case has become not only about Amarin, it's about dozens of bio startups.
Count me in for $100
I love how google translates "generic" medicine: "copy" and "counterfeit"
Happy to hear about your results!
15-20% at the most